World Health Organization site
Skip Navigation Links

Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ISRCTN
Last refreshed on: 14 July 2014
Main ID:  ISRCTN04280032
Date of registration: 29/07/2010
Primary sponsor: Bio-Manguinhos/Fiocruz (Brazil)
Public title: Disposable-Syringe Jet Injector for Measles-Mumps-Rubella vaccine (DSJI MMR) study DSJI/MMR
Scientific title: A randomised, non-inferiority study comparing safety and immunogenicity of a disposable-syringe jet injector to needle and syringe for the administration of measles-mumps-rubella combination vaccine to healthy Brazilian infants aged 12 to 18 months
Date of first enrolment: Jul 26 2010
Target sample size: 582 children
Recruitment status: Completed/Not recruiting
Study type:  Interventional
Study design:  Randomised controlled non-inferiority study  
Countries of recruitment
Name: Reinaldo  Martins
Address:  Av. Brasil 4365 Manguinhos 21040-360 Rio de janeiro Brazil
Telephone: +55 21 3882 9497
Key inclusion & exclusion criteria
Inclusion criteria: 1. Healthy children from 12 to 18 months of age, either sex
2. Up-to-date with their immunisation schedule according to age
3. Not enrolled in other clinical studies

Exclusion criteria: 1. Parents/guardians unable or unwilling to give consent for the study
2. Unable to follow the study procedures

Age minimum:
Age maximum:
Health Condition(s) or Problem(s) studied
Measles, mumps and rubella vaccination
MMR vaccine, against measles, mumps and rubella (Schwarz, RIT 4385 and Wistar RA 27/3 strains, respectively), to be administered as a single 0.5 mL dose, subcutaneously, delivered by a needle-free device (experimental group) or by the conventional needle and syringe method (control group), in a 2:1 proportion,
that is, 388 volunteers allocated to the experimental group and 194 to the control group. Volunteers will be followed-up for 42 days after vaccination. Blood collections for immunogenicity before vaccination and 42 days after vaccination. Adverse events will be registered in diary cards by parents/guardians during this period.
Primary Outcome(s)
Antibody titres 42 days after vaccination: cut offs for enzyme-linked immunosorbent assay (ELISA) 231 units/mL (mumps) and 4 IU/mL for rubella. Plaque reduction neutralisation test (PRNT) for measles, cut off 0.20 IU/mL.
Secondary Outcome(s)
Local and systemic adverse events during 42 days after vaccination
Secondary ID(s)
Source(s) of Monetary Support
1. Bill and Melinda Gates Foundation (USA) - PATH DSJI project 2. Bio-Manguinhos/Fiocruz (Brazil)
Secondary Sponsor(s)
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.1 - Version history